ASCO develops and maintains quality measures through a rigorous process that aligns with the CMS Measures Blueprint and National Quality Forum’s standards. Measure concepts are vetted, prioritized, specified, and tested according to clinical importance, evidence, gaps in care, and variation in treatment. Multidisciplinary panels of experts develop ASCO’s clinical quality measures. ASCO provides oversight on the use of measures in quality programs and initiatives including  the CMS Quality Payment Program  (QPP), Merit-based Incentive Payment System (MIPS), and Alternative Payment Model (APM) tracks; the QOPI Reporting Registry; and the Quality Oncology Program Initiative (QOPI®).

Measures Steering Group

The Measures Steering Group (MSG) oversees the prioritization, development, approval, testing, and maintenance of clinical quality measures. The MSG’s activities also include oversight of the technical expert measure panels, collaborative measure development projects, review of externally developed measures, and represent ASCO before quality improvement and measures organizations. The MSG operates under the ASCO Quality of Care Council (QCC).

Measure Technical Expert Panels

ASCO's evidence-based measure development process, supported by robust member engagement through expert panels, represents the interests and needs of clinicians who deliver oncology care. Currently, over 60 members directly support ASCO’s measure development efforts through participation in numerous standing multi-disciplinary Technical Expert Panels (TEPs). These TEP members make significant contributions to the Society's de novo measure development and measure maintenance strategies by providing clinical expertise and guidance on measure concepts, level and quality of evidence, and measure specifications.

During de novo measure development, TEP chairs and members share their clinical expertise and guidance throughout the measure development lifecycle, which comprises measure conceptualization, specification, testing, and implementation. ASCO's rigorous, evidence-based measure development process reflects standards established by the Blueprint for the CMS Measures Management System and incorporates critical components, such as environmental scanning and literature review, empirical data and gap analysis, stakeholder engagement, and testing of measure validity, feasibility, and reliability.

During measure maintenance, TEP members are provided with full measure specifications, new evidence, historical measure performance data, and any external feedback or requests for clarification or updates received by staff.

Measure Technical Expert Panels (TEPs):

  • Core & Cross-cutting
  • Breast & Gynecologic Oncology
  • End of Life & Palliative Care
  • Gastrointestinal
  • Genitourinary
  • Hematologic Malignancies
  • Immuno-oncology
  • Melanoma
  • Thoracic

If you would like to participate, visit the ASCO Volunteer Portal to volunteer to serve.

Oncology Measures Advisory Group

The Oncology Measures Advisory Group (OMAG) is an innovative effort to facilitate measure utilization; promote appropriate, high-quality cancer care; and advance strategies for measuring and reporting performance information by fostering collaborative efforts between critical stakeholders. Members will come together under the purview of the Conquer Cancer Council, a sub-group of The ASCO Foundation, to meet and discuss topics of mutual interest.  

The OMAG mission is to improve quality of cancer care across healthcare settings.  This multi-stakeholder forum will help to identify meaningful measures in oncology, improving patients’ health by recognizing and promoting exceptional quality in cancer care.   

The goals of the OMAG are to: 

  • Identify high-value, high-impact, evidence-based measures that promote better patient outcomes, and provide useful information for improvement, decision-making and payment 
  • Address important aspects of care for which quality measures are underdeveloped or non-existent  
  • Strategize ideas about the modernization of quality measures that our healthcare industry relies upon 
  • Reduce the burden of measurement by eliminating low-value metrics, redundancies, and inconsistencies in measure specifications and quality measure reporting requirements across quality programs 
  • Provide critical insight on the best ways to align the measures used across quality programs 
  • Spur development of electronic clinical quality measures through use of EHR data 
  • Drive outcome-based healthcare measurement that better reflects the voices of patients and caregivers 

Principles of ASCO Measurement 

It is important to note that the OMAG will not participate in the technical development of measures or measure sets. The OMAG will provide guidance and advice to Conquer Cancer and ASCO subject to the understanding that ASCO’s measures are developed in accordance with ASCO priorities and measurement science principles, and that ASCO has the sole discretion to determine which measures it ultimately develops, based on its current priorities and principles below. 

  • ASCO measures are independently developed through a transparent process; 
  • ASCO measures are evidence based; 
  • ASCO measures are derived from published guidelines where a guideline is available;  
  • Development and validation of measures follow guidelines standards for patient privacy and human research protection;  
  • While process measures are important, ASCO gives priority to outcome measures;  
  • Reviewing and updating ASCO measures when there are changes in evidence or practice is an ASCO priority. 

How to join the OMAG 

The OMAG is a subgroup of the Conquer Cancer Council (CCC). For additional information, please contact